Table 5.

Clinicopathological variables associated with optimal cytoreduction in patients with endometrial carcinoma

	Complete cytoreduction	Univariate		P value	Multivariate		P value
	(N%)	HR	95% CI		HR	95% CI
Age at recurrence (years)
< 60	26 (81.3)	1
≥ 60	12 (80.0)	1.083	0.231–5.081	0.919
ECOG performance status before SCS
0	32 (78.0)
1–2	6 (100.0)	NA	NA	0.579
FIGO stage at initial diagnosis
I/II	31 (88.6)	1			1
III/IV	7 (58.3)	5.536	1.175–26.072	0.030	30.777	1.167-811.458	0.040
Histology
Endometrioid	33 (86.8)	1			1
Non-endometrioid	5 (55.6)	5.280	1.048–26.589	0.044	0.820	0.08–8.359	0.867
Tumor grade
G1/G1-G2/G2	18 (94.7)	1
G2-G3/G3	15 (78.9)	4.8	0.483–47.682	0.181
Previous radiotherapy
No	31 (79.5)	1
Yes	7 (87.5)	0.554	0.059–5.173	0.604
Clinical symptoms at recurrence
No	21 (80.8)	1
Symptomatic	17 (81.0)	0.988	0.229–4.264	0.987
Size of largest tumor (cm)
≤ 6	35 (85.4)	1
> 6	3 (50.0)	5.833	0.946–35.988	0.057
Number of recurrent tumors
One	23 (95.8)	1			1
Several	15 (65.2)	12.267	1.389-108.325	0.024	20.050	1.222-329.049	0.036
DFI before SCS (months)
< 12	16 (76.2)	1
≥ 12	22 (84.6)	0.582	0.135–2.515	0.468
Retroperitoneal lymph node metastasis
No	28 (75.7)
Yes	10 (100.0)	NA	NA	0.172
Distant metastasis
No	30 (78.9)	1
Yes	8 (88.9)	0.469	0.051–4.137	0.504
Lung metastasis alone
No	37 (80.4)
Yes	1 (100.0)	NA	NA	1.000
Peritoneal dissemination
No	33 (89.2)	1			1
Yes	5 (50.0)	8.250	1.638–41.546	0.011	1.833	0.049–69.231	0.744
Extended beyond the pelvis
No	21 (95.5)	1			1
Yes	17 (68.0)	9.882	1.123–86.985	0.039	0.386	0.013–11.546	0.583
Ascites
None	36 (87.8)	1			1
Yes	2 (33.3)	14.400	2.073-100.012	0.007	26.009	0.294-2301.929	0.154
Neoadjuvant chemotherapy before SCS
No	35 (79.5)
Yes	3 (100.0)	NA	NA	1.000

SCS, Secondary cytoreductive surgery; ECOG, Eastern Cooperative Oncology Group; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; CI, confidence intervals; DFI, Disease-free interval